Indium (In111) Chloride Curium Netherlands

Indium-111 chloride, the active ingredient in Indium (In111) Chloride Curium Netherlands, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed to label white blood cells and bind to specific targets, enabling diagnostic imaging of infection, inflammation, and tumor sites in patients.

GNH USA supplies Indium (In111) Chloride Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and research institutions worldwide, providing reliable access to high‑quality radiopharmaceuticals for diagnostic imaging.

Indium-111 chloride is used in diagnostic imaging procedures targeting infection, inflammation and tumor detection. - Infection and inflammation imaging: enables visualization of active infection or inflammatory sites by labeling autologous white blood cells for scintigraphy. - Tumor imaging and localization: assists in detecting and delineating malignant lesions through targeted radiolabeling of tumor‑associated markers. - Diagnostic scintigraphy: provides gamma emission for gamma‑camera imaging in various nuclear medicine studies.

Indium-111 chloride may be associated with adverse reactions following intravenous administration. Common Side Effects: - Injection site pain: mild discomfort at the site of injection. - Transient flushing: brief feeling of warmth or redness. - Nausea: mild, self‑limiting nausea. - Headache: occasional mild headache. Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate treatment. - Radiation‑induced leukopenia: reduction in white blood cell count after high cumulative exposure. - Severe hypotension: marked drop in blood pressure following injection. - Organ toxicity: rare injury to kidneys or liver due to radiation.

Prior to using Indium-111 chloride, several precautions should be observed to ensure patient safety and optimal imaging results. - Pregnancy: use only when benefits outweigh potential fetal radiation risk. - Breastfeeding: discontinue nursing or consider alternative imaging agents. - Renal impairment: evaluate kidney function as excretion may be reduced. - Concurrent radiopharmaceuticals: avoid overlapping studies within 24 hours to prevent excess radiation. - Radiation safety: apply ALARA principles and protect staff with shielding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 chloride can interact with certain drugs or procedures that affect radiation exposure or hematologic status. Major Interactions (Avoid): - Concurrent high‑dose iodine therapy: may interfere with imaging interpretation. - Other radiopharmaceuticals within 24 h: risk of cumulative radiation dose. - Chemotherapeutic agents causing bone‑marrow suppression: increased risk of hematologic toxicity. Moderate Interactions (Monitor Closely): - Antihistamines: may mask mild allergic responses to the tracer. - Beta‑blockers: could alter hemodynamic response during injection. - Contrast media: may modify biodistribution of the radiotracer.